DUSA Pharmaceuticals To Pay U.S. $20.75 Million To Settle False Claims Act Allegations Relating To Promotion Of Unsupported Drug Administration Process
Massachusetts-based DUSA Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries, has agreed to pay $20.75 million to resolve allegations that it knowingly promoted a process for administering its drug Levulan Kerastick that contradicted the product instructions approved by the FDA, and was unsupported by sufficient clinical evidence.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.